Jennifer Riley - 01 Jan 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Strategy Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
01 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 16:06:16 UTC
Next filing
12 Dec 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 01 Jan 2025 Common Stock 150,000 $7.43 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the Option Shares vest on January 1, 2026 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.